Business Description
Champions Oncology Inc
NAICS : 325414
SIC : 2836
ISIN : US15870P3073
Description
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.58 | |||||
| Equity-to-Asset | -0.08 | |||||
| Debt-to-Equity | -3.76 | |||||
| Debt-to-EBITDA | -1.14 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -2.73 | |||||
| Beneish M-Score | -2.81 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.6 | |||||
| 3-Year EBITDA Growth Rate | -36.6 | |||||
| 3-Year EPS without NRI Growth Rate | -29.2 | |||||
| 3-Year FCF Growth Rate | 11.8 | |||||
| 3-Year Book Growth Rate | -5.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 3.26 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.18 | |||||
| 9-Day RSI | 45.68 | |||||
| 14-Day RSI | 44.67 | |||||
| 6-1 Month Momentum % | -17.3 | |||||
| 12-1 Month Momentum % | 0.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.6 | |||||
| Quick Ratio | 0.6 | |||||
| Cash Ratio | 0.2 | |||||
| Days Sales Outstanding | 35.64 | |||||
| Days Payable | 61.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.1 | |||||
| Shareholder Yield % | 2.3 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 40.09 | |||||
| Operating Margin % | -17.87 | |||||
| Net Margin % | -19.76 | |||||
| FCF Margin % | -13.65 | |||||
| ROE % | -417.94 | |||||
| ROA % | -31.29 | |||||
| ROIC % | -30.81 | |||||
| ROC (Joel Greenblatt) % | -61.75 | |||||
| ROCE % | -88.66 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.38 | |||||
| EV-to-EBIT | -8.19 | |||||
| EV-to-EBITDA | -10.59 | |||||
| EV-to-Revenue | 1.46 | |||||
| EV-to-Forward-Revenue | 1.26 | |||||
| EV-to-FCF | -10.72 | |||||
| Price-to-Median-PS-Value | 0.49 | |||||
| Earnings Yield (Greenblatt) % | -12.21 | |||||
| FCF Yield % | -9.85 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers